Pembrolizumab + Trametinib
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
KRAS Gene Mutation
Conditions
KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Trial Timeline
Jun 26, 2018 → Jun 25, 2024
NCT ID
NCT03299088About Pembrolizumab + Trametinib
Pembrolizumab + Trametinib is a phase 1 stage product being developed by Merck for KRAS Gene Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT03299088. Target conditions include KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma.
What happened to similar drugs?
0 of 2 similar drugs in KRAS Gene Mutation were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03299088 | Phase 1 | Completed |
Competing Products
20 competing products in KRAS Gene Mutation